ARFGEF2 Knockdown Enhances TNF-a Induced Endothelial Expression of the Cell Adhesion Molecules VCAM1 and ICAM1*
Daniel A. Dworkis1,2, Elizabeth S. Klings1, Sherene M. Shenouda, Nadia Solovieff, Efthymia Melista, Carl Giovannucci, Surinder Safaya, Guihua Li, Joseph A. Vita, Martin H. Steinberg, Clinton T. Baldwin
Open Journal of Blood Diseases
Cells used in publication:
Endothelial, MV lung, human (HMVEC-L)
Tissue Origin: lung
Endothelial, MV dermal (HMVEC-d), human
Tissue Origin: dermal
Endothelial Cell Growth Medium 2
Endothelial Cell Growth Medium-2 Microvascular
Sickle cell anemia (SCA) is an autosomal-recessive hemoglobinopathy with a highly variable phenotype. Multiple clinical complications are characteristic of SCA including inflammatory and oxidant damage to both small and large blood vessels, hemolysis, vasoocclusion, and premature mortality. The overall severity of SCA is affected by multiple genetic modifier loci, including ARFGEF2, a gene known to modify TNF-a receptor release from human endothelial cells. In this report, we examine the effect of siRNA mediated knockdown of ARFGEF2 in human pulmonary artery endothelial cells and report that TNF-a induced expression of ICAM1 and VCAM1, both important mediators of endo- thelial-leukocyte adhesion, is significantly enhanced after ARFGEF2 knockdown. Levels of ICAM-1 protein are also increased in TNF-a treated endothelial cells after ARFGEF2 knockdown; the increased ICAM-1 appears to be localized in the cytoplasm. IL-1ß stimulation of endothelial cells without ARFGEF2 produced enhanced ICAM1 expression only. Additionally, ARFGEF2 knockdown distinctly altered endothelial cell morphology. Large-vessel pathology in SCA is believed to begin with endothelial activation by inflammatory cytokines and adhesion of sickle erythrocytes and leuko- cytes, leading to a progressive vasculopathy characterized by smooth muscle cell migration and proliferation. Under- standing how variability in the function of ARFGEF2 alters the response of pulmonary vasculature to TNF-a might suggest new targets for SCA treatment.
©2023 Lonza. All rights reserved.